Diabetic nephropathy and anaemia

European Journal of Clinical Investigation, Supplement

Volumn 35, Issue 3, 2005, Pages 66-74

  Ritz, E ^a   Haxsen, V ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anaemia; Congestive heart failure; Diabetic nephropathy; Diabetic retinopathy; Erythropoietin; Renal failure

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ERYTHROCYTE DISORDER; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IATROGENIC DISEASE; IRON DEFICIENCY; KIDNEY FUNCTION; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TISSUE INJURY;

EID: 28944433052     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01544.x     Document Type: Review

References (113)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.
2. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34:795-808.
3. Schwenger V, Müssig C, Hergesell O, Zeier M, Ritz E. [Incidence and clinical characteristics of renal insufficiency in diabetic patients]. Dtsch Med Wochenschr 2001;126:1322-6.
4. Schwenger V, Hofmann A, Khalifeh N, Meyer T, Zeier M, Hörl WH et al. [Uremic patients - late referral, early death]. Dtsch Med Wochenschr 2003;128:1216-20.
5. Elachkar T, Ohmit SE, Grimm R, Bakris G, Flack JM. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency. Diabetes 2002;51:A224 (abstract).
6. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401-8.
7. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003;26:1164-9.
8. Ishimura E, Nishizawa Y, Okuno S, Matsumoto N, Emoto M, Inaba M et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 1998;11:83-6.
9. Dikow R, Schwenger V, Schömig M, Ritz E. How should we manage anaemia in patients with diabetes? Nephrol Dial Transplant 2002;17 (Suppl. 1):67-72.
10. Kojima K, Totsuka Y. Anemia due to reduced serum erythropoietin concentration in non-uremic diabetic patients. Diabetes Res Clin Pract 1995;27:229-33.
11. Cotroneo P, Maria Ricerca B, Todaro L, Pitocco D, Manto A, Ruotolo V et al. Blunted erythropoietin response to anemia in patients with Type 1 diabetes. Diabetes Metab Res Rev 2000;16:172-6.
12. Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR et al. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract 1999;46:223-9.
13. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001;24:495-9.
14. White KE, Bilous RW. Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease. J Am Soc Nephrol 2000;11:1667-73.
15. Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003;14:1396-405.
16. Takaku F, Hirashima K, Okinaka S. Effect of the bilateral section of the splanchnic nerve on erythropoiesis. Naturwissenschaften 1961;191:500-1.
17. Beynon G. The influence of the autonomic nervous system in the control of erythropoietin secretion in the hypoxic rat. J Physiol 1977;266:347-60.
18. Biaggioni I, Robertson D, Krantz S, Jones M, Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 1994;121:181-6.
19. Eckardt KU, LeHir M, Tan CC, Ratcliffe PJ, Kaissling B, Kurtz A. Renal innervation plays no role in oxygen-dependent control of erythropoietin mRNA levels. Am J Physiol 1992;263:F925-30.
20. Cole J, Ertoy D, Lin H, Sutliff RL, Ezan E, Guyene TT et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin- converting enzyme-deficient mice. J Clin Invest 2000;106:1391-8.
21. Savary K, Corvol P, Gasc JM. Angiotensin-converting enzyme (ACE): ontogenesis and possible role in blood islands development. European Council for Blood Pressure and Cardiovascular Research, Seeheim 10-12 October 2003;PK 4 (abstract).
22. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 1996;97:839-44.
23. De La Tour DD, Raccah D, Jannot MF, Coste T, Rougerie C, Vague P et al. Pase activity and diabetes: relationship with C-peptide level. Diabetologia;41:1080-4.
24. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med;37:826-30.
25. Rigalleau V, Blanchetier V, Aparicio M, Baillet L, Sneed J, Dabadie H et al. Erythropoietin can deteriorate glucose control in uraemic non-insulin-dependent diabetic patients. Diabetes Metab 1998 1998;24:62-5.
26. Macdougall IC. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999;14:1836-41.
27. Inomata S, Itoh M, Imai H, Sato T. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron 1997;75:426-30.
28. Garcia DL, Anderson S, Rennke HG, Brenner BM. Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988;85:6142-6.
29. Donnelly S, Shah BR. Erythropoietin deficiency in hyporeninemia. Am J Kidney Dis 1998;33:947-53.
30. Bayes B, Serra A, Junca J, Lauzurica R. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin. Nephrol Dial Transplant 1998;13:1894-5.
31. Ishimitsu T, Ono H, Sugiyama M, Asakawa H, Oka K, Numabe A et al. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron 1996;74:607-10.
32. Vaziri ND, Kaupke CJ, Barton CH, Gonzales E. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Am J Med 1992;92:35-40.
33. Nowicki M, Kokot F, Kokot M, Bar A, Dulawa J. Renal clearance of endogenous erythropoietin in patients with proteinuria. Int Urol Nephrol 1994;26:691-9.
34. Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55.
35. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58.
36. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-13.
37. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-induced changes in retinal NAD-redox status: pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 2001;62:172-80.
38. Wiessner C, Allegrini PR, Ekatodramis D, Jewell UR, Stallmach T, Gassmann M. Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J Cereb Blood Flow Metab 2001;21:857-64.
39. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 1997;78:1505-9.
40. Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale L. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost 1997;77:1020-4.
41. Beguin Y. Erythropoietin and platelet production. Haematologica 1999;84:541-7.
42. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-9.
43. Shaskey DJ, Green GA. Sports haematology. Sports Med 2000;29:27-38.
44. Lage JM, Panizo C, Masdeu J, Rocha E. Cyclist's doping associated with cerebral sinus thrombosis. Neurology 2002;58:665.
45. Wagner KF, Katschinski DM, Hasegawa J, Schumacher D, Meller B, Gembruch U et al. Chronic inborn erythrocytosis leads to cardiac dysfunction and premature death in mice overexpressing erythropoietin. Blood 2001;97:536-42.
46. Bode-Böger SM, Böger RH, Kuhn M, Radermacher J, Frölich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996;50:1255-61.
47. Barrett JD, Zhang Z, Zhu JH, Lee DB, Ward HJ, Jamgotchian N et al. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 1998;16:1749-57.
48. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991;261:E642-6.
49. Noguchi K, Yamashiro S, Matsuzaki T, Sakanashi M, Nakasone J, Miyagi K. Effect of 1-week treatment with erythropoietin on the vascular endothelial function in anaesthetized rabbits. Br J Pharmacol 2001;133:395-405.
50. Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T. Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens 1999;12:980-7.
51. Roger SD, Grasty MS, Baker LR, Raine AE. Effects of oxygen breathing and erythropoietin on hypoxic vasodilation in uremic anemia. Kidney Int 1992;42:975-80.
52. Allegra A, Buemi M, Corica F, Aloisi C, Frisina N. Erythropoietin administration induces an increase of serum levels of soluble E-selectin and soluble intercellular adhesion molecule 1. Nephron 1999;82:361-2.
53. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990;87:5978-82.
54. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-8.
55. Carlini RG, Alonzo EJ, Dominguez J, Bianca I, Weisinger JR, Rothstein M et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 1999;55:546-53.
56. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36.
57. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000;97:11609-13.
58. Migliori M, Taccola D, Panichi V, De Pietro S, Andreini B, Di Benedetto A et al. Kidney Blood Press Res 1999;22:140-5.
59. Gross SS. Vascular biology. Targeted delivery of nitric oxide. Nature 2001;409:577-8.
60. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S et al. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 2003;9:1498-505.
61. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003;9:496-500.
62. Kielstein JT, Böger RH, Bode-Böger SM, Schaffer J, Barbey M, Koch KM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
63. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis 1995;26:875-88.
64. Bidani AK, Mitchell KD, Schwartz MM, Navar LG, Lewis EJ. Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model. Kidney Int 1990;38:28-38.
65. Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003;14:S173-7.
66. Krmar RT, Gretz N, Klare B, Wuhl E, Schärer K. Renal function in predialysis children with chronic renal failure treated with erythropoietin. Pediatr Nephrol 1997;11:69-73.
67. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307-12.
68. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176-85.
69. Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Goubina I, Fulcher G et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant 2004;19:1792-7.
70. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005;165:466-9.
71. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005;67:1483-8.
72. Spallone V, Maiello MR, Kurukulasuriya N, Barini A, Lovecchio M, Tartaglione R et al. Does autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric type 2 diabetic patients? Diabet Med 2004;21:1174-80.
73. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-8.
74. Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Goubina I, Fulcher G et al. Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 2004;89:4359-63.
75. Thomas MC, Tsalamandris C, MacIsaac R, Medley T, Kingwell B, Cooper ME et al. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int 2004;66:1167-72.
76. Sinclair SH. Introduction. Semin Ophthalmol 1999;14:197-9.
77. Sinclair SHI, Vecchio C, Levin A. Treatment of anemia in the diabetic patient with retinopathy and kidney disease. Am J Ophthalmol 2003;135:740-3.
78. Qiao Q, Keinanen-Kiukaanniemi S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997;50:153-8.
79. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998;39:233-52.
80. Shorb SR. Anemia and diabetic retinopathy. Am J Ophthalmol 1985;100:434-6.
81. Melberg NS, Grand MG, Rup D. The impact of acute lymphocytic leukemia on diabetic retinopathy. J Pediatr Hematol Oncol 1995;17:81-4.
82. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis 1995;26:202-8.
83. Grimm C, Wenzel A, Groszer M, Mayser H, Seeliger M, Samardzija M et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002;8:718-24.
84. Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, Reina M, Vilaro S et al. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003;18:2538-44.
85. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002;99:10659-64.
86. Hassan K, Simri W, Rubenchik I, Manelis J, Gross B, Shasha SM et al. Effect of erythropoietin therapy on polyneuropathy in predialytic patients. J Nephrol 2003;16:121-5.
87. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
88. Dikow R, Ritz E. Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrol Dial Transplant 2003;18:1993-8.
89. Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997;40:1307-12.
90. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32.
91. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34.
92. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003;64:610-5.
93. Collins AJ. The hemoglobin link to adverse outcome. Advanced Studies Med 2003;3:S194-S7.
94. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223-5.
95. Silverberg DS, Wexler D, Blum M, Sheps D, Schwartz D, Yachnin T et al. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia stops or slows the progression of both diseases. Perit Dial Int 2001;21 (Suppl. 3):S236-40.
96. Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141-6.
97. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000;15 (Suppl. 3):14-8.
98. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 2002: 35-8.
99. Eckardt KU. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplant 1999;14:1317-23.
100. Levin A. Preaching and practice: evidence-based medicine and the accountability of nephrologists within the health care system. The implications of the findings of the cost-saving potential of subcutaneous versus intravenous epoetin therapy. Am J Kidney Dis 2002;40:662-3.
101. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-90.
102. Macdougall IC, Ritz E. The Normal Haematocrit Trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998;13:3030-3.
103. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
104. Heeschen C, Aicher A, Lehmann R, Fichtischerer S, Vasa M, Urbich C et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-6.
105. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003;64:1648-52.
106. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-6.
107. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
108. Masuda S, Nagao M, Sasaki R. Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int J Hematol 1999;70:1-6.
109. Shyu KG, Wang MT, Wang BW, Chang CC, Leu JG, Kuan P et al. Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002;54:576-83.
110. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 1999;126:3597-605.
111. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8:495-505.
112. Wakeen M, Zimmerman SW. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998;32:488-93.
113. Schömig M, Ritz E, Standl E, Allenberg J. The diabetic foot in the dialyzed patient. J Am Soc Nephrol 2000;11:1153-9.